Bavarian Nordic has initiated two Phase III clinical trials of its mpox vaccine, Jynneos, in pregnant and breastfeeding women ...

First studies to evaluate MVA-BN in infants under 2 years of age and pregnant and breastfeeding women.The multi-partner ...

Bavarian Nordic initiates clinical trials of mpox vaccine in infants and pregnant women: Copenhagen, Denmark Saturday, June 28, 2025, 12:00 Hrs [IST] Bavarian Nordic A/S, a global ...

The FDA approval of Vimkunya has given the chikungunya vaccine’s owner, Bavarian Nordic, an extra financial windfall. | The ...

First studies to evaluate MVA-BN in infants under 2 years of age and pregnant and breastfeeding women.The multi-partner research project is aimed at expanding access to mpox vaccines for vulnerable ...

Sale prices for the vouchers – which slash FDA review times for a drug – have increased in the past year as biotech funding ...

Bavarian Nordic A/S (OMX: BAVA) announced today that it has entered into an agreement to sell its Priority Review Voucher ...

Danish vaccine specialist Bavarian Nordic (OMX: BAVA) is set to collect $160 million from the sale of a US priority review ...

Bavarian Nordic was awarded the PRV in February 2025, following the approval by the U.S. Food and Drug Administration of the chikungunya vaccine, VIMKUNYA™ for prevention of disease caused by ...

MVA-BN vaccine shown to be safe and 84% effective against mpox in HIV-negative people. Real-world data support rollout in ...